SR9009
SR9009 (stenabolic)
Also known as: Stenabolic
A REV-ERB agonist marketed as an exercise mimetic; animal data only, very poor oral bioavailability, and published work questioning whether its effects even run through REV-ERB.
Overview
SR9009 modulates the circadian nuclear receptor REV-ERB and, in a 2012 Nature paper, changed metabolism and reduced fat in mice. It has no human trials. Later studies showed it is barely absorbed orally and short-lived, and that some of its cellular effects occur in cells lacking REV-ERB, so the marketed story does not match the pharmacology.
Mechanism of action
REV-ERB alpha/beta agonism affecting circadian regulation of metabolism (contested).
Key studies & citations
- Animal2012
Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists
Metabolic effects in mice.
Nature - In vitro2018
SR9009 effects independent of REV-ERB
Effects persisted in REV-ERB-deficient cells.
Biochemical Pharmacology
Frequently asked questions
Does oral SR9009 work?
Its oral bioavailability is very low and its half-life short. No human study supports the marketed benefits.